MacroGenics Inc (MGNX)
Drugs • Health Care
July 23, 2026 MacroGenics Inc. Announces Promising Clinical Update for MGC026 MacroGenics announces positive developments in its Phase 1 study of MGC026, a B7-H3-targeted ADC for advanced solid tumors, with no severe side effects reported. The findings will be showcased at ESMO 2026, highlighting potential efficacy and safety in oncology.
July 02, 2026 MacroGenics Completes Strategic Manufacturing Operations Sale to Bora Pharmaceuticals MacroGenics has completed the sale of its GMP drug manufacturing operations to Bora Pharmaceuticals for $122.5 million. This strategic move allows MacroGenics to focus on developing cancer therapies while Bora enhances its manufacturing capabilities.
June 22, 2026 MacroGenics Secures $24.5 Million Milestone Payment from Sanofi Following TZIELD® Approval MacroGenics announced a $24.5 million milestone payment from Sanofi after the FDA approved TZIELD® for delaying type 1 diabetes. This approval marks a significant advancement in diabetes treatment and opens potential for further financial gains.
May 14, 2026 MacroGenics to Showcase Innovations at Stifel 2026 Virtual Targeted Oncology Forum MacroGenics is set to showcase its advancements in cancer therapeutics at the Stifel 2026 Virtual Targeted Oncology Forum. CEO Eric Risser will discuss the company's strategic direction and innovations on May 20, 2026. The event will be accessible via webcast, with a replay available for 30 days.
May 04, 2026 MacroGenics Expands Royalty Agreement with Sagard Healthcare Partners MacroGenics has expanded its royalty agreement with Sagard Healthcare Partners, receiving $60 million upfront and potential future earnings based on ZYNYZ®'s sales. This strategic move enhances MacroGenics' financial position while allowing them to retain key interests in their cancer treatment portfolio.
April 08, 2026 FDA Lifts Partial Clinical Hold on MacroGenics' LINNET Study: A Significant Milestone in Cancer Therapeutics MacroGenics has received FDA approval to lift the partial clinical hold on its LINNET study for lorigerlimab, a treatment for advanced ovarian cancer. The decision allows for new participant enrollment under a revised protocol to enhance patient safety. This milestone is crucial for the development of innovative cancer therapies.
March 09, 2026 MacroGenics Inc. Reports Financial Results and Strategic Advances in 2025 MacroGenics, Inc. has released its financial results for 2025, showcasing a promising outlook for 2026. Key highlights include advancements in their ADC pipeline and strategic partnerships, alongside expectations for critical clinical data and regulatory updates.
March 09, 2026 MacroGenics Inc. Reports 2025 Annual Financial Results: Navigating Challenges in the Biopharmaceutical Landscape MacroGenics Inc. reported a net income loss of $74.62 million for 2025, with total revenue slightly down. Key shifts in revenue sources and strategic partnerships are discussed as the company navigates financial challenges in the oncology sector.
February 26, 2026 MacroGenics Inc. Announces Participation in Major Investor Conferences MacroGenics, Inc. will present at several major investor conferences in March 2026, highlighting its advancements in cancer therapeutics. The company will provide webcasts of the presentations for those unable to attend, enhancing investor engagement and showcasing its innovative pipeline.
February 23, 2026 MacroGenics Pauses Enrollment in LINNET Trial Amid FDA Clinical Hold MacroGenics has paused enrollment in its LINNET trial for lorigerlimab following a partial clinical hold from the FDA due to serious patient safety events. The company highlights its commitment to patient safety and aims to resume enrollment as soon as possible, while current participants will continue receiving treatment.
November 25, 2025 MacroGenics Set to Showcase Innovations at Evercore Healthcare Conference MacroGenics will showcase its advancements in cancer therapeutics at the Evercore Healthcare Conference on December 4, 2025. CEO Eric Risser will discuss the company's innovative antibody-based treatments and strategic initiatives. Stakeholders can access the live webcast for key insights into MacroGenics' future in biopharmaceuticals.
November 12, 2025 MacroGenics Reports Third Quarter 2025 Financial Results and Corporate Updates MacroGenics reports a Q3 2025 revenue decline to $72.8 million, down from $110.7 million, alongside significant corporate updates. The company focuses on future growth through strategic partnerships and advancing its antibody-drug conjugates despite challenges in collaboration revenue.
November 12, 2025 MacroGenics Inc. Reports Q3 2025 Financial Results: A Decrease in Revenue Amid Strategic Collaborations MacroGenics Inc. has announced its Q3 2025 financial results, revealing a significant revenue decline primarily due to reduced milestone payments and product sales. Despite challenges, the company is focusing on operational efficiency and strategic partnerships to enhance its oncology pipeline.
November 06, 2025 MacroGenics Inc. Set to Shine at Stifel 2025 Healthcare Conference MacroGenics, Inc. will participate in the Stifel 2025 Healthcare Conference on November 13, 2025, where CEO Eric Risser will discuss the company's advancements. Investors can access the presentation via a webcast, with an archived replay available for 30 days. MacroGenics focuses on innovative cancer treatments through its proprietary technologies.
August 14, 2025 MacroGenics Inc. Reports Q2 2025 Financial Results: A Mixed Bag of Growth and Challenges MacroGenics Inc. reported Q2 2025 financial results, showcasing a revenue increase to $22.24 million, driven by strategic collaborations. However, challenges persist with net product sales and an increasing accumulated deficit. The company continues to innovate in oncology while managing operational costs effectively.
May 13, 2025 MacroGenics Inc. Reports Q1 2025 Financial Results: A Mixed Bag of Progress MacroGenics Inc. reports a revenue increase in Q1 2025, driven by collaborations with Gilead and Incyte, despite net losses and product sales challenges. The company continues to advance its innovative pipeline in oncology.
March 20, 2025 MacroGenics Inc. Reports Mixed Results in 2024 Annual Financial Report MacroGenics Inc. reported a substantial revenue increase to $149.9 million in 2024, driven by collaborative agreements despite a decline in product sales. The company faces challenges including high operational costs, leadership changes, and legal proceedings as it prepares for future growth.
March 20, 2025 MacroGenics Inc. Reports 2024 Financial Results and Corporate Progress MacroGenics, Inc. reported significant financial growth for 2024, achieving $150 million in revenue. The company highlighted key clinical milestones and future studies in cancer treatment, signaling promising developments ahead.
March 12, 2025 SWOT Analysis of MacroGenics Inc in 2025 This SWOT analysis of MacroGenics Inc in 2025 highlights the company's strengths in innovative cancer therapies and collaboration, while addressing weaknesses like financial dependency. The analysis also explores growth opportunities and competitive threats in the evolving biopharmaceutical landscape.
March 06, 2025 MacroGenics Inc. Announces Upcoming Financial Results Conference Call MacroGenics, a biopharmaceutical innovator, will announce its fourth quarter and full year 2024 financial results on March 20, 2025. Investors can participate via conference call or webcast, gaining insights into the company's fiscal health and strategic direction in cancer treatment.
February 27, 2025 MacroGenics Inc. Set to Showcase Innovations at Upcoming Investor Conferences MacroGenics, Inc. will present at several major investor conferences in March 2025, showcasing its innovative cancer therapies and strategic vision. CEO Dr. Scott Koenig will lead discussions on the company's developments, with webcasts available for those unable to attend.
November 05, 2024 MacroGenics Inc. Reports Strong Q3 2024 Results Amidst Industry Challenges MacroGenics Inc. reported a remarkable Q3 2024, achieving $110.7 million in revenue, driven by strategic partnerships. Despite industry challenges, the company shows a promising financial trajectory with significant net income growth and continued investment in R&D.
August 06, 2024 MacroGenics Inc. Reports Q2 2024 Financial Results: A Mixed Picture Amid Strategic Advancements MacroGenics Inc. announced its Q2 2024 financial results, revealing a significant revenue decline to $2.3 million and a net loss of $55.66 million. Despite the downturn, the company remains committed to its R&D efforts and has made strides in its product pipeline, raising questions about future revenue generation amid strategic collaborations.
May 09, 2024 MacroGenics Inc. Reports Q1 2024 Financial Results: A Closer Look at Challenges and Opportunities MacroGenics Inc. reported a net loss of $43.4 million for Q1 2024, with revenue down to $24.1 million. The company's focus on R&D remains strong despite financial challenges, supported by strategic partnerships for future growth.